Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
Active, not recruiting · NCT03950609 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Multiple Primary, Neoplasms, Nerve Tissue, digestive system neuroendocrine neoplasm, endocrine system disorder, hereditary disease, hereditary neoplastic syndrome, malignant endocrine neoplasm, multiple endocrine neoplasia, multiple endocrine neoplasia type 1, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-09-18 | NCT03950609 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
| National Cancer Institute (NCI) | 3015 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| M D Anderson Cancer Center | Houston | United States | 667 |